Microbiome Market

The microbiome refers to a collection of microorganisms, including bacteria, fungi, and viruses, that reside in a specific environment. Within the human body, the microbiome encompasses the genetic material of all the bacteria, fungi, protozoa, and viruses. Bacteria in the microbiome play crucial roles in digestion, immune system regulation, defense against harmful bacteria, and the production of essential vitamins such as Vitamin K, B12, thiamine, and riboflavin.

There are two primary types of microbiome applications: faecal microbiota transplantation (FMT) and microbiome drugs. Faecal microbiota transplantation, also known as stool transplantation, involves transferring bacteria and other microorganisms from a healthy individual to another person. Various technologies such as genomics, proteomics, and metabolomics are utilized in areas like inflammatory bowel disease, diabetes, multiple sclerosis, and rheumatoid arthritis.

The Business Research Company offers a comprehensive microbiome market research report that presents statistics, global market size, regional shares, competitors' market share, detailed market segments, trends, opportunities, and additional data necessary for success in the microbiome industry. This report provides a thorough analysis of the present and future scenarios in the industry.

The global microbiome market size is projected to grow from $0.39 billion in 2022 to $0.57 billion in 2023, with a compound annual growth rate (CAGR) of 45.6%. The Russia-Ukraine war has disrupted global economic recovery from the COVID-19 pandemic, impacting multiple countries with economic sanctions, commodity price surges, supply chain disruptions, and inflation. Nonetheless, the global microbiome market is expected to reach $1.09 billion by 2027, growing at a CAGR of 17.6%.

The increasing prevalence of inflammatory bowel disease (IBD) is a significant driver of the microbiome market's growth. IBD, which includes ulcerative colitis (UC) and Crohn's disease (CD), is a multifactorial autoimmune disorder. Microbial therapies like fecal microbiota transplantation (FMT) and probiotics have shown potential in restoring microbial balance and reducing inflammation in immune-mediated disorders like IBD. These therapies have demonstrated the ability to induce remission, particularly in UC. For instance, in September 2020, the National Institute of Health, a US-based biomedical and public health research agency, reported promising results of microbial therapies in IBD treatment.

The microbiome market is expected to grow due to the increasing prevalence of inflammatory bowel disease (IBD), which affects between 600,000 and 900,000 Americans.

One of the challenges faced by the microbiome market is the high cost of microbial therapy. The price of fecal transplantation, a common microbial therapy, can vary significantly depending on factors such as the treatment method, location, insurance coverage, and other variables. This high cost is anticipated to hinder the growth of the microbiome market.

A notable trend in the microbiome market is the growing focus on technological advancements. Key companies in the industry are actively developing advanced technology solutions for microbiomes. For example, Seed, a new microbiome company, has introduced the Probiotic and Prebiotic Daily Synbiotic, which offers strain-specific benefits beyond digestive health, such as cardiac safety, dermatological health, immune control, reproductive health, gut barrier integrity, and oxidative stress management.

In January 2021, Denmark-based biotechnology company Novozymes acquired Microbiome Labs, a probiotics company based in the United States, to expand its Human Health platform. This acquisition provides Novozymes with access to a range of patented solutions and an extensive network of healthcare professionals.

Key players in the microbiome market include MicroBiome Therapeutics LLC., Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc., AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc., and ViThera Pharmaceuticals Inc.

North America was the largest region in the microbiome market in 2022. The global microbiome market report covers regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The report includes countries like Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The microbiome market encompasses the sales of firmicutes, bacteroidetes, and actinobacteria. The market value represents the revenues earned by enterprises from the sale of goods and/or services within the specified market and geography.

The global microbiome market is segmented -
1) By Type: Fecal Microbiota Transplantation (FMT), Microbiome Drugs
2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Other Applications
3) By Technology: Genomics, Proteomics, and Metabolomics